AT494910T - Composition packaged virus-like particles comprising for enhancing an immune response - Google Patents

Composition packaged virus-like particles comprising for enhancing an immune response

Info

Publication number
AT494910T
AT494910T AT04763176T AT04763176T AT494910T AT 494910 T AT494910 T AT 494910T AT 04763176 T AT04763176 T AT 04763176T AT 04763176 T AT04763176 T AT 04763176T AT 494910 T AT494910 T AT 494910T
Authority
AT
Austria
Prior art keywords
enhancing
particles
immune response
composition packaged
packaged virus
Prior art date
Application number
AT04763176T
Other languages
German (de)
Inventor
Martin Bachmann
Katrin Schwarz
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US48571703P priority Critical
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Priority to PCT/EP2004/007679 priority patent/WO2005004907A1/en
Publication of AT494910T publication Critical patent/AT494910T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse Transcribing DNA Viruses
    • C12N2730/00011Reverse Transcribing DNA Viruses
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse Transcribing DNA Viruses
    • C12N2730/00011Reverse Transcribing DNA Viruses
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse Transcribing DNA Viruses
    • C12N2730/00011Reverse Transcribing DNA Viruses
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/10011Arenaviridae
    • C12N2760/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/467The waterborne disease being caused by a virus of the genus Polyomavirus: JC virus or BK virus, i.e. Polyomavirus infection
AT04763176T 2003-07-10 2004-07-12 Composition packaged virus-like particles comprising for enhancing an immune response AT494910T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US48571703P true 2003-07-10 2003-07-10
PCT/EP2004/007679 WO2005004907A1 (en) 2003-07-10 2004-07-12 Packaged virus-like particles

Publications (1)

Publication Number Publication Date
AT494910T true AT494910T (en) 2011-01-15

Family

ID=34062090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04763176T AT494910T (en) 2003-07-10 2004-07-12 Composition packaged virus-like particles comprising for enhancing an immune response

Country Status (11)

Country Link
US (1) US20060251623A1 (en)
EP (1) EP1644034B1 (en)
JP (1) JP2009513532A (en)
KR (1) KR20060031607A (en)
CN (1) CN100404070C (en)
AT (1) AT494910T (en)
AU (1) AU2004255470B2 (en)
CA (1) CA2527102A1 (en)
DE (1) DE602004031017D1 (en)
RU (1) RU2375076C2 (en)
WO (1) WO2005004907A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
AT544466T (en) 2002-10-29 2012-02-15 Coley Pharm Group Inc Use of CpG oligonucleotides for treatment of hepatitis C virus infection
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
AU2004224761A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
ES2217967B1 (en) * 2003-03-31 2006-01-01 Bionostra, S.L. Method of producing empty virus particles (VLPs) of inductor virus infectious bursal disease (IBDV), compositions necessary for tuning and use in vaccine development against IBDV.
ES2307346B1 (en) * 2004-01-21 2009-11-13 Bionostra, S.L. Empty capsids (VLPs (-VP4)) of the virus causing the disease infectious bursal disease (IBDV), the procedure for obtaining and applications.
ES2307345B1 (en) * 2004-01-21 2009-11-13 Bionostra, S.L. Empty chimeric capsids of the virus causing the disease infectious bursal disease (IBDV), the procedure for obtaining and applications.
AU2005291231B2 (en) * 2004-10-05 2010-12-23 Cytos Biotechnology Ag VLP-antigen conjugates and their uses as vaccines
NZ561040A (en) * 2005-03-18 2009-04-30 Cytos Biotechnology Ag Cat allergen fusion proteins and use thereof
JP2009501001A (en) * 2005-06-01 2009-01-15 ダウ グローバル テクノロジーズ インコーポレイティド Production of multivalent virus-like particles
ES2310062B1 (en) * 2005-07-15 2009-11-13 Bionostra, S.L. Pseudovirales derived chimeric empty particles of the virus causing the disease of infectious bursal disease (IBDV), obtaining process and applications.
SI2032592T1 (en) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
RU2451523C2 (en) * 2005-12-14 2012-05-27 Цитос Биотехнологи Аг Particles packed in immunostimulating nucleic acid that intended for hypersensitivity treatment
AU2013204383B2 (en) * 2006-06-12 2016-09-22 Kuros Biosciences Ag Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
JP4957886B2 (en) * 2006-06-30 2012-06-20 東レ株式会社 Column with immune activation ability
CA2671873C (en) * 2006-12-12 2018-10-09 Brian Stephen Sproat Oligonucleotides containing high concentrations of guanine monomers
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2010024284A1 (en) * 2008-09-01 2010-03-04 国立大学法人 北海道大学 Anti-viral vaccine for fish, immunostimulating agent for fish, and immunostimulation method for fish
WO2010042749A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042755A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010042751A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
ES2560782T3 (en) * 2008-11-04 2016-02-22 Index Pharmaceuticals Ab Compounds and methods for treating CNS inflammatory diseases
NZ596058A (en) * 2009-04-30 2013-08-30 Cytos Biotechnology Ag Influenza hemagglutinin compositions and uses thereof
DE102009034779A1 (en) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetic analogs of bacterial lipopeptides and their use for the treatment and prevention of allergic diseases
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CA2835972A1 (en) * 2011-05-13 2012-11-22 Folia Biotech Inc. Virus-like particles and process for preparing same
CN103945863A (en) * 2011-08-01 2014-07-23 爱默蕾大学 Vlps containing ligands and methods related thereto
EP3275464A1 (en) * 2011-08-01 2018-01-31 Emory University Vlps containing ligands and methods related thereto
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
MX2014007262A (en) 2011-12-22 2014-08-01 Hoffmann La Roche Full length antibody display system for eukaryotic cells and its use.
WO2013113326A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
CN103421117B (en) * 2012-05-16 2016-08-03 李岱宗 An immune Enhanced virus-like particle expression vector preparation and application
WO2015172128A1 (en) * 2014-05-09 2015-11-12 Indiana University Research And Technology Corporation Methods and compositions for treating hepatitis b virus infections
EA201791598A1 (en) 2015-01-15 2017-12-29 Юниверсити Оф Копенгаген Virus-like particle with an effective exposure of epitopes
EP3436066A1 (en) * 2016-04-01 2019-02-06 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69133566D1 (en) * 1990-01-12 2007-04-26 Amgen Fremont Inc Formation of xenogenic antibodies
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2267100T5 (en) * 1994-07-15 2011-04-08 Coley Pharmaceutical Group, Inc. Immunomodulatory oligonucleotides.
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP2002514397A (en) * 1998-05-14 2002-05-21 コーリー ファーマシューティカル グループ,インコーポレイテッド The method of Hematomodulators using CpG oligonucleotides
WO2001022972A2 (en) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
ES2309178T3 (en) * 2001-09-13 2008-12-16 Airsage, Inc. System and method for providing traffic information using operational data developed by a wireless network.
WO2003024480A2 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP2196217A1 (en) * 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
CN1662253A (en) * 2002-06-20 2005-08-31 赛托斯生物技术公司 Packaged virus-like particles for use as adjuvants: method of preparation and use

Also Published As

Publication number Publication date
CN100404070C (en) 2008-07-23
AU2004255470B2 (en) 2010-08-19
EP1644034B1 (en) 2011-01-12
US20060251623A1 (en) 2006-11-09
WO2005004907A1 (en) 2005-01-20
JP2009513532A (en) 2009-04-02
DE602004031017D1 (en) 2011-02-24
CN1802173A (en) 2006-07-12
RU2006103853A (en) 2007-08-20
AU2004255470A1 (en) 2005-01-20
CA2527102A1 (en) 2005-01-20
EP1644034A1 (en) 2006-04-12
KR20060031607A (en) 2006-04-12
RU2375076C2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
DE60232456D1 (en) The curable composition
AT397942T (en) Adjuvant to increase the immune response with respect to polynucleotide-based vaccines
DE60217367D1 (en) Nanoparticle compositions containing insulin
DE502004001833D1 (en) Clutch release
DE60221715D1 (en) Device for preparation of baby food
DE60215857D1 (en) An orthodontic device
AT458041T (en) New trichoderma-generated
AT460113T (en) Device for blutgefäsdetektion
DE60236385D1 (en) Getränkeherstellungsvorrichtung- and methods
DE602004022496D1 (en) System for particle therapy
DE602004013976D1 (en) suspension
DE60235523D1 (en) adhesive composition
DE60327807D1 (en) Gel-coated compositions with delayed release
AT517162T (en) silicone primer compositions objects enthalted
AT555741T (en) An orthodontic device
AT538783T (en) Arrangement for improving the effective receptor
DE602005009729D1 (en) System for the preparation of beverages
DE602004010893D1 (en) Polytrimethylenetherdiolhaltige coating compositions
AT397426T (en) Device for improving the mitral valve
NO20044326D0 (en) viral antigens
AT406863T (en) Dental compositions and methods with arylsulfinatsalzen
AT538188T (en) polishing composition
AT417591T (en) Device for compacting powder
AT516321T (en) Compositions containing olefins fluorosubstituierten
DE602004024694D1 (en) slip coat

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties